OraSure Technologies, Inc. (OSUR) Receives $10.00 Average Price Target from Brokerages

OraSure Technologies, Inc. (NASDAQ:OSUR) has been assigned a consensus rating of “Sell” from the seven analysts that are currently covering the company, MarketBeat.com reports. Three analysts have rated the stock with a sell rating and two have issued a hold rating on the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $10.00.

A number of equities analysts recently issued reports on the stock. BidaskClub downgraded shares of OraSure Technologies from a “hold” rating to a “sell” rating in a research note on Thursday. ValuEngine downgraded shares of OraSure Technologies from a “hold” rating to a “sell” rating in a research note on Monday, February 4th. Zacks Investment Research downgraded shares of OraSure Technologies from a “hold” rating to a “sell” rating in a research note on Wednesday, May 15th. Finally, Canaccord Genuity downgraded shares of OraSure Technologies from a “buy” rating to a “hold” rating and set a $10.00 price target for the company. in a research note on Thursday, May 9th.

Shares of NASDAQ:OSUR opened at $8.21 on Thursday. The stock has a market cap of $509.44 million, a PE ratio of 16.42, a PEG ratio of 2.95 and a beta of 1.16. The company has a quick ratio of 6.56, a current ratio of 7.52 and a debt-to-equity ratio of 0.02. OraSure Technologies has a 12 month low of $8.08 and a 12 month high of $17.97.

OraSure Technologies (NASDAQ:OSUR) last released its quarterly earnings results on Wednesday, May 8th. The medical instruments supplier reported ($0.05) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.06) by $0.01. OraSure Technologies had a net margin of 11.34% and a return on equity of 7.87%. The company had revenue of $30.12 million during the quarter, compared to the consensus estimate of $29.66 million. During the same period in the prior year, the firm earned $0.07 earnings per share. OraSure Technologies’s revenue was down 28.3% on a year-over-year basis. On average, equities analysts anticipate that OraSure Technologies will post 0.23 earnings per share for the current year.

In related news, CEO Stephen S. Phd Tang sold 16,667 shares of the stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $11.10, for a total value of $185,003.70. Following the completion of the transaction, the chief executive officer now directly owns 135,627 shares of the company’s stock, valued at $1,505,459.70. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, SVP Jack E. Jerrett purchased 10,000 shares of the firm’s stock in a transaction that occurred on Monday, May 13th. The stock was bought at an average cost of $8.55 per share, with a total value of $85,500.00. The disclosure for this purchase can be found here. Over the last three months, insiders purchased 21,000 shares of company stock valued at $184,360. 1.70% of the stock is owned by insiders.

A number of hedge funds have recently added to or reduced their stakes in the stock. BlueMountain Capital Management LLC grew its holdings in OraSure Technologies by 4,352.6% in the first quarter. BlueMountain Capital Management LLC now owns 73,779 shares of the medical instruments supplier’s stock worth $823,000 after purchasing an additional 72,122 shares during the period. HighTower Advisors LLC grew its holdings in OraSure Technologies by 6.9% in the first quarter. HighTower Advisors LLC now owns 55,583 shares of the medical instruments supplier’s stock worth $622,000 after purchasing an additional 3,605 shares during the period. Man Group plc grew its holdings in OraSure Technologies by 108.4% in the first quarter. Man Group plc now owns 19,847 shares of the medical instruments supplier’s stock worth $222,000 after purchasing an additional 10,322 shares during the period. SEI Investments Co grew its holdings in OraSure Technologies by 996.6% in the first quarter. SEI Investments Co now owns 3,597 shares of the medical instruments supplier’s stock worth $33,000 after purchasing an additional 3,269 shares during the period. Finally, Goldman Sachs Group Inc. grew its holdings in OraSure Technologies by 4.0% in the first quarter. Goldman Sachs Group Inc. now owns 238,734 shares of the medical instruments supplier’s stock worth $2,662,000 after purchasing an additional 9,292 shares during the period. 91.93% of the stock is owned by institutional investors.

OraSure Technologies Company Profile

OraSure Technologies, Inc, together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. It operates in two segments, OSUR and DNAG. The company also offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests.

Recommended Story: How to find the components of the quick ratio

Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with MarketBeat.com's FREE daily email newsletter.